• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Biohaven (BHVN) Cheap As Pipeline Progress And The Ono Deal Lift Interest?

    Simply Wall St·11/09/2026 02:28:54
    Listen to the news

    Biohaven (BHVN) has come back into focus after a busy stretch of scientific and commercial updates, including new Graves' disease data, membranous nephropathy findings and a US$80 million regional licensing deal with Ono Pharmaceutical.

    Against that backdrop, Biohaven’s share price has been volatile but net positive, with a 1-day share price return of 4.17%, a 30-day share price return of 19.87% and a year-to-date share price return of 33.58%. The 1-year total shareholder return of 75.30% contrasts with a 3-year total shareholder return that is down 49.37%, which hints that recent enthusiasm is building on the back of fresh clinical and licensing updates after a tougher earlier period for long-term holders.

    Scan Biohaven’s recent surge alongside hand-picked biopharma peers that are pushing new modalities into late stage trials by running the 19 high quality undiscovered gems.

    Biohaven now has a deep pipeline, fresh licensing cash and a sharply higher share price. The question is whether that mix is fairly reflected in today’s valuation.

    Most Popular Narrative: 66% Undervalued

    Biohaven last closed at $14.48, while the most followed valuation storyline anchors fair value at $42.29. The gap between price and narrative is wide and grounded in specific pipeline and funding expectations that matter for anyone tracking the stock.

    The pivotal Phase 3 trial of BHV-1300 in Graves’ disease, as a first MoDE extracellular protein degrader targeting pathogenic IgG1 TSH receptor autoantibodies, creates a potential new autoimmune revenue stream that is largely separate from epilepsy and could improve earnings diversification if successful.

    The planned pivotal studies for BHV-1400 in IgA nephropathy and advanced trials for oncology candidates BHV-1510 and BHV-1530, including a Regeneron combination study, open up additional indications that could layer on new revenue lines and allow fixed R&D and SG&A costs to be spread over a wider product mix, which can support margin expansion over time.

    See why 0 investors see Biohaven as 66% undervalued.

    The narrative uses a discount rate of 7.74% and a fair value of $42.29, which implies Biohaven is viewed as materially undervalued relative to that framework, even though the business is currently loss making and not forecast to reach profitability over the next three years.

    The same storyline leans heavily on very large modeled revenue growth, with forecasts pointing to a move from effectively no current sales to $287.7 million by around 2029, and assumes profit margins eventually line up with the wider US biotech sector despite present net losses of $542.7 million and negative equity on the balance sheet.

    To align with the most optimistic analyst cohort, the narrative suggests investors would be underwriting a future P/E of 213.9x on those 2029 earnings, a level far above the current sector multiple of 18.8x. This highlights how much outcome risk around trials, funding and competition is embedded in that $42.29 fair value.

    Result: Fair Value of $42.29 (UNDERVALUED)

    Still, the partial FDA hold on opakalim, along with Biohaven’s ongoing cash burn and potential shareholder dilution, sit in the background as clear swing factors for that bullish script.

    Find out about the key risks to this Biohaven narrative.

    Next Steps

    If this Biohaven story feels finely balanced between promise and pressure, move fast, stress test the numbers yourself and weigh both sides of the argument. To see the full picture of potential upsides and the issues investors are worried about, review the 2 key rewards and 6 important warning signs.

    Looking for more Biohaven sized ideas?

    If Biohaven has sharpened your appetite for opportunity, do not stop here. Broaden your watchlist with focused stock ideas that match your risk and income goals.